PCI Biotech announces preliminary outcome of meetings with EMA and FDA for development of fimaporfin in inoperable cholangiocarcinoma

Posted on Dec 20, 2017

Oslo, 20 December 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced preliminary outcome of regulatory interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) on the development of fimaporfin in combination with gemcitabine for treatment of inoperable cholangiocarcinoma (bile duct cancer). The purpose of […]

Third quarter 2017 report and presentation

Posted on Nov 28, 2017

Oslo, 28 November 2017 – Please find enclosed the financial report and presentation for third quarter 2017. PCI Biotech Q3 2017 Report PCI Biotech Q3 2017 Presentation Granting of orphan status from the FDA was an important milestone for the fimaCHEM programme during Q3 2017, as was the inclusion of the first patient in the […]

Invitation to third quarter 2017 presentation

Posted on Nov 21, 2017

Oslo, 21 November 2017 – PCI Biotech invites to a presentation of the company’s third quarter 2017 report on Tuesday 28 November 2017 at Oslo Cancer Cluster Innovation Park. Time: Tuesday November 28, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo […]